Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,608,464
since: 14 May 2006

TMS Therapy improves quality of life for moderate-to-severely depressed

posted Wednesday, 23 May 2007

New research presented at the American Psychiatric Association's (APA) annual meeting on patients with moderate-to-severe depression, who had not received adequate benefit from previous antidepressant therapy, demonstrated that Transcranial Magnetic Stimulation Therapy significantly improved quality of life and functioning when compared to patients receiving sham (placebo) treatment.

"Symptom control is only meaningful in so far as it improves patients' ability to function and enjoy life, which is an essential part of the recovery process," said H. Brent Solvason, MD, PhD, Assistant Professor of Psychiatry at Stanford University. Dr. Solvason was a primary investigator in the NeuroStar TMS Therapy studies and is the lead author of this data report. "Ideally, the combination of both symptomatic and functional improvement should be the goal of treatment."

At baseline, the study population (N = 301) had significant symptomatic and functional impairment related to depression. After four weeks of treatment, patients receiving NeuroStar TMS Therapy (N = 155) experienced statistically significant improvements in the General Health (P = 0.049) and Mental Health (P = 0.006) subscales, as well as Mental Component Score (P = 0.019) of the SF-36, a widely used health outcomes measure. After six weeks, significant improvements were also seen in the SF-36 Role- Emotional (P = 0.044) subscale and the Quality of Life Enjoyment and Satisfaction Questionnaire — Q-LES-Q (P = 0.035), a common measurement tool used to assess quality of life in patients suffering from depression. The effect sizes observed in functional status improvement were similar in magnitude to the effect sizes observed in symptomatic benefit.

"These data demonstrate that NeuroStar TMS Therapy produced significant improvements in depressive symptoms that were accompanied by concurrent improvements in patient-reported functional status and quality of life," said Dr. Solvason.

A second trial presented at APA evaluated the acute efficacy of TMS Therapy in an open-label setting, which more closely resembles real-world clinical practice. In the open-label study, TMS Therapy was administered as monotherapy in 158 patients for a six week period. At the end of six weeks, there was a three week taper phase, which included co-administration of medication monotherapy.

Patients treated with TMS Therapy experienced a significant improvement in symptoms, from baseline, as early as Week Two. TMS Therapy-treated patients also achieved a 42 percent response rate and a 27 percent remission rate at the end of six weeks, as measured by the 24-item Hamilton Depression Rating Scale (HAMD-24). At the end of the taper phase, the response rate increased to 46 percent and the remission rate increased to 37 percent. The response rate is the percentage of patients who experienced at least a 50 percent improvement in symptoms. The remission rate is the percentage of patients who experienced a virtually complete resolution of symptoms.

"The clinical significance of the treatment benefit is demonstrated by the substantial proportion of patients who achieved both response and the more stringent outcome of remission," said Mark A. Demitrack, MD, Chief Medical Officer for Neuronetics, a psychiatrist, and an author of the study. "The clinical significance of these data can also be demonstrated by comparison with the recently reported outcomes from the large, open-label STAR*D treatment study. Remission rates with NeuroStar TMS Therapy observed in this study met or exceeded those reported for STAR*D when patients were stratified by level of prior treatment failure."


Solvason HB, Husain MM, Fitzgerald PB, et al.
TMS in the Acute Treatment of Major Depression: Improvements in Functional Status and Quality of Life
APA Annual meeting, 2007, session NR332

Janicak PG, O'Reardon JP, Sampson SM, et al.
Safety and Tolerability of TMS in the Treatment of Major Depression: Evidence From Extended Exposure and Reintroduction Treatment
APA Annual meeting, 2007, session NR316

tags:    

links: digg this    del.icio.us    technorati    reddit